HUTCHMED Secures NMPA Approval for ORPATHYS® in MET-Amplified Gastric Cancer
Event summary
- HUTCHMED's ORPATHYS® (savolitinib) received conditional NMPA approval for treating locally advanced or metastatic gastric cancer with MET amplification after at least two prior treatments failed.
- The approval is based on a Phase II study showing an objective response rate of 32.3% and a disease control rate of 63.1%.
- ORPATHYS® is the third approved indication for HUTCHMED in China, with AstraZeneca as its commercialization partner.
- MET amplification affects approximately 4-6% of gastric cancer patients, with an estimated annual incidence of 18,000 cases in China.
The big picture
This approval solidifies HUTCHMED's position in biomarker-driven precision medicine, particularly in gastrointestinal oncology. The strategic partnership with AstraZeneca underscores a broader industry trend toward targeted therapies addressing unmet needs in cancer treatment. With ORPATHYS® now approved for three indications in China, HUTCHMED is poised to strengthen its commercial footprint in the world's second-largest pharmaceutical market.
What we're watching
- Commercialization Pace
- The speed at which AstraZeneca can scale ORPATHYS®'s commercial availability in China and potentially expand into other markets.
- Clinical Expansion
- Whether HUTCHMED and AstraZeneca will accelerate further clinical development for ORPATHYS® in combination therapies or additional tumor types.
- Regulatory Momentum
- How this approval influences the regulatory pathway for other MET inhibitors or precision oncology drugs in China.
Related topics